Chloroquine Market Size, Share & Forecast Analysis to 2030

The global chloroquine market size was valued at around USD 1 billion in 2025 and expected to grow at a significant CAGR of over 4% during the forecast period from 2026 to 2030. The market is witnessing steady growth due to the continued demand for affordable antimalarial therapies, particularly in malaria-endemic regions across Africa and Asia-Pacific. Government-led malaria control programs and international health initiatives remain key factors supporting market expansion. The malaria treatment segment accounts for the largest market share, driven by the high prevalence of the disease in developing countries. Additionally, the availability of generic formulations and established distribution networks enhances market accessibility.

Market Snapshot:

Market Insights:

• Malaria Treatment is the dominant application segment, driven by the continued need for affordable antimalarial therapies in endemic regions.
• Tablets account for the largest share by type due to their ease of administration, cost-effectiveness, and widespread availability.
• Africa dominates the market, supported by the region’s high malaria burden and extensive public health treatment programs.
• Rising government initiatives and international funding for malaria control continue to support market demand and drug accessibility.

Key Factors Driving the Chloroquine Market Growth

The growth of the chloroquine market is primarily driven by the persistent burden of malaria in endemic regions, particularly across Africa, Asia-Pacific, and parts of Latin America. Chloroquine remains an important antimalarial therapy in areas where Plasmodium vivax and other chloroquine-sensitive malaria strains are prevalent. Government-supported malaria control programs, public health initiatives, and the widespread availability of low-cost generic formulations continue to support demand. In addition, the drug’s established role in treating certain autoimmune disorders, such as rheumatoid arthritis and lupus, contributes to its sustained market presence.

Another key driver is the increasing investment in infectious disease management and healthcare infrastructure in developing economies. Despite advancements in newer antimalarial therapies, chloroquine remains a cost-effective treatment option in several countries. A recent WHO report highlighted that global malaria cases reached approximately 282 million in 2024, with around 610,000 deaths, underscoring the continued need for accessible antimalarial medications and supporting long-term demand for chloroquine-based treatments.

Key Growth Drivers:

• High prevalence of malaria in endemic regions across Africa, Asia-Pacific, and Latin America continues to drive demand for chloroquine-based treatments, particularly in areas with chloroquine-sensitive malaria strains.
• Government-led malaria control and eradication programs supported by international organizations are increasing the procurement and distribution of affordable antimalarial drugs, boosting market growth.
• Cost-effectiveness and widespread availability of generic formulations make chloroquine a preferred treatment option in developing countries, while its use in autoimmune disease management provides additional demand support.

Global Chloroquine Market Restraints:

One of the primary restraints affecting the chloroquine market is the widespread emergence of chloroquine-resistant malaria parasites, particularly Plasmodium falciparum. Resistance has significantly reduced the drug’s effectiveness in many malaria-endemic regions, prompting healthcare authorities to recommend alternative therapies such as artemisinin-based combination treatments (ACTs). As a result, the use of chloroquine has declined in several countries, limiting its market expansion and reducing demand in regions with high resistance rates.

Another major challenge is the availability of newer and more effective antimalarial drugs along with concerns regarding adverse effects associated with long-term chloroquine use. Prolonged treatment can lead to side effects such as retinopathy, cardiotoxicity, and gastrointestinal complications, necessitating careful patient monitoring. Additionally, stricter regulatory requirements for pharmaceutical products and increasing investments in advanced malaria therapies may further restrict the growth potential of the chloroquine market over the forecast period.

Growth Opportunities in the Global Chloroquine Market

The chloroquine market offers substantial opportunities in emerging economies where malaria remains a major public health challenge and affordable treatment options are essential. Expanding healthcare infrastructure, increased government spending on infectious disease management, and broader access to essential medicines are expected to support market growth. Additionally, the continued use of chloroquine for selected autoimmune disorders such as lupus and rheumatoid arthritis creates opportunities for manufacturers to diversify their revenue streams beyond antimalarial applications.

Another significant opportunity stems from the ongoing expansion of global malaria control and treatment programs. According to the Global Fund’s 2025 Malaria Report, programs supported by the organization tested 360 million suspected malaria cases, treated 173 million malaria cases, and distributed 162 million insecticide-treated mosquito nets in 2024. These large-scale malaria prevention and treatment efforts highlight the continued need for accessible antimalarial therapies, creating favorable long-term demand prospects for chloroquine and related medications in endemic regions.

Key Growth Opportunities:

• Expansion of malaria control programs in endemic countries is increasing demand for affordable antimalarial medicines, creating opportunities for chloroquine manufacturers to strengthen their presence in public healthcare systems.
• Growing healthcare investments in emerging economies are improving access to diagnosis and treatment services, supporting the wider distribution and adoption of chloroquine-based therapies.
• Sustained use in autoimmune disease management, particularly for lupus and rheumatoid arthritis, provides an additional growth avenue beyond malaria treatment and helps diversify market revenue sources.

Industry Trends Shaping the Global Chloroquine Market

A key trend in the chloroquine market is the increasing emphasis on expanding access to affordable antimalarial medicines in endemic regions. Governments and healthcare organizations are strengthening procurement programs, while pharmaceutical companies continue to increase the production of generic formulations to improve treatment availability. This trend is particularly important in low- and middle-income countries, where cost-effective malaria therapies remain essential for disease management.

Another notable trend is the growing global commitment to malaria research and innovation. According to the Medicines for Malaria Venture (MMV), its portfolio currently includes more than 70 active research and access projects focused on developing and improving malaria treatments and prevention strategies. This ongoing investment in malaria innovation is enhancing disease-control efforts worldwide and creating a supportive environment for both established and next-generation antimalarial therapies.

Market Segments Insights:

By Type: The Tablets Segment Dominated the Global Chloroquine Market

The global chloroquine market is bifurcated into type, application, distribution channel, and geography. On the basis of type, the tablets segment dominated the market, accounting for the largest share due to their widespread use in malaria treatment and prevention programs. Their affordability, ease of storage, long shelf life, and simple administration make them the preferred dosage form across both developed and developing countries. Tablets are extensively distributed through hospitals, clinics, retail pharmacies, and government healthcare initiatives, particularly in malaria-endemic regions where large-scale treatment programs are common.

The segment’s dominance is further supported by the strong availability of generic chloroquine tablets and high patient acceptance for outpatient treatment. Unlike injectables, which are primarily reserved for hospital settings and severe cases, tablets are suitable for routine therapy and prophylactic use, enabling broader adoption. Their cost-effectiveness and accessibility continue to make tablets the leading product type in the global chloroquine market.

By Application: The Malaria Treatment Sub-category Holds the Largest Revenue Share of the Global Chloroquine Market

On the basis of application, the global chloroquine market is further segmented into malaria treatment, autoimmune diseases, amebiasis treatment, and others. The malaria treatment is the dominant application segment in the market, holding the largest market share due to the drug’s long-standing role in the treatment and prevention of malaria. Chloroquine continues to be widely utilized in regions where Plasmodium parasites remain susceptible to the drug, particularly in parts of Africa, Asia-Pacific, and Latin America. Government-backed malaria control programs, international health initiatives, and the need for affordable treatment options further contribute to the segment’s dominance.

The segment’s leadership is also supported by the high global burden of malaria and the large number of patients requiring effective antimalarial therapies each year. Compared with autoimmune disease and amebiasis applications, malaria treatment generates significantly higher demand volumes due to widespread public health procurement and large-scale distribution programs. The drug’s established efficacy, accessibility, and low cost continue to make malaria treatment the primary revenue-generating application within the global chloroquine market.

The chloroquine market research report presents the analysis of each segment from 2020 to 2030 considering 2025 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2026 to 2030.

Global Chloroquine Market Segmentation:

By Type:

• Tablets
• Injectables
• Capsules

By Application:

• Malaria Treatment
• Autoimmune Diseases
• Amebiasis Treatment
• Others

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis: Why Africa is the Dominant Region in the Global Chloroquine Market

Geographically, the Africa is the dominant region in the chloroquine market, accounting for the largest share due to the region’s exceptionally high malaria burden and continued demand for affordable antimalarial therapies. Many countries across sub-Saharan Africa rely on large-scale public health programs, government procurement initiatives, and international aid-supported treatment campaigns to combat malaria. The widespread prevalence of the disease, combined with the need for cost-effective medications, makes Africa the primary revenue-generating region for chloroquine manufacturers.

The region’s dominance is further reinforced by the concentration of global malaria cases and deaths within Africa. According to the latest World Malaria Report 2025, the WHO African Region accounted for approximately 95% of global malaria cases (265 million cases) and 95% of malaria deaths (579,000 deaths) in 2024, highlighting the immense demand for malaria prevention and treatment interventions across the continent. This substantial disease burden continues to support the consumption of antimalarial drugs, including chloroquine in areas where the drug remains clinically effective.

Competitive Analysis:

The chloroquine market is characterized by intense competition among generic pharmaceutical manufacturers, as chloroquine is a well-established drug with widespread global availability. Companies compete primarily on pricing, product quality, regulatory compliance, and distribution capabilities. The market is supported by demand from government healthcare programs, hospitals, and public health agencies, particularly in malaria-endemic regions. Manufacturers with strong production capacities and extensive distribution networks are better positioned to secure long-term supply contracts and expand their market presence.

Leading players such as Sanofi, Ipca Laboratories Ltd., Zydus Lifesciences Ltd., Cipla Limited, and Teva Pharmaceutical Industries Ltd. focus on expanding their geographic reach, maintaining regulatory standards, and strengthening supply chain efficiency. Competitive differentiation is increasingly driven by manufacturing reliability, participation in public-sector procurement programs, and the ability to provide cost-effective formulations, particularly in regions with a high malaria burden.

Key Companies:

• Sanofi
• Ipca Laboratories Ltd.
• Zydus Lifesciences Ltd.
• Cipla Limited
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Cadila Pharmaceuticals
• Strides Pharma Science Limited
• Taj Pharmaceuticals
• Bayer AG
• Lupin Limited
• Aurobindo Pharma Limited

Global Chloroquine Market Outlook

• Steady market growth is expected due to the continued demand for affordable antimalarial therapies in malaria-endemic regions.
• Government-led malaria control and elimination programs will remain a key driver of chloroquine consumption in applicable markets.
• Expansion of healthcare infrastructure in emerging economies is likely to improve access to malaria diagnosis and treatment.
• Growing generic drug production and distribution networks will enhance product availability and support market penetration.
• Demand from autoimmune disease treatment applications is expected to provide additional growth opportunities beyond malaria management.

Global Chloroquine Market FAQs: